联系我们Contact us
1. 基(ji)本信(xin)息
品系名称 NOD. Prkdcscid Il2rgtm1 Vst Tg(Csf1p -IL3)Vst/Vst
常用名 hIL-3 NPG /Vst; hIL-3 NPG
背景 NOD-scid/NcrCrl
毛色 白色
品系建立：
采用转基(ji)因的方法，构建pCDNA3.1-Csf1p-IL3载体，将线性化Csf1p-IL3表达序列注射到(dao)NPG小鼠(shu)的原核中，在获得(de)的后(hou)代中筛选到(dao)合适表达量的阳性小鼠(shu)。
在(zai)隔离(li)器(qi)中，按照近交(jiao)的方式扩繁建立商(shang)品化的hIL-3 NPG小鼠(shu)品系。
2. 表(biao)型
在(zai)NPG小鼠(shu)(shu)中表达(da)人(ren)的(de)hIL-3细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)因子(zi)。白细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)介素3刺激多能(neng)造血(xue)(xue)干(gan)(gan)细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)分化(hua)为髓系祖细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)。可(ke)以与(yu)(yu)表达(da)人(ren)GM-CSF、M-CSF细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)因子(zi)的(de)NPG小鼠(shu)(shu)一起，在(zai)移(yi)植(zhi)人(ren)CD34+造血(xue)(xue)干(gan)(gan)细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)6-8周后(hou)，于外周血(xue)(xue)、骨(gu)髓、胸(xiong)腺和(he)脾(pi)脏以及包括(kuo)肺和(he)肝在(zai)内的(de)非淋巴组(zu)织中，形成稳定广泛的(de)髓系和(he)淋巴系细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)分化(hua)。在(zai)血(xue)(xue)液和(he)组(zu)织中，可(ke)检测到(dao)粒细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)分化(hua)（嗜碱性(xing)粒细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)、中性(xing)粒细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)和(he)肥大细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)），抗(kang)原呈递细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)分化(hua)（树突(tu)状细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)和(he)巨噬细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)）和(he)调节性(xing)T细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)群(qun)体(ti)等(deng)。表达(da)人(ren)M-CSF、GM-CSF和(he)人(ren)IL-3细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)因子(zi)与(yu)(yu)Hu-NPG人(ren)源化(hua)小鼠(shu)(shu)相比，人(ren)类(lei)造血(xue)(xue)干(gan)(gan)细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)（hsc）的(de)整(zheng)体(ti)植(zhi)入水平更高，分化(hua)细(xi)(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)种类(lei)更多。
3. 应用领(ling)域
-人源化(hua)和癌症治疗
-人体过敏(min)反(fan)应(ying)模型(xing)，免疫(yi)、造血移植重建模型(xing)
-再生医学
-感染性疾(ji)病
-生物医学
4. 参考文献
（1）Ito R, Takahashi T, Katano I, Kawai K, Kamisako T, Ogura T, Ida-Tanaka M, Suemizu H, Nunomura S, Ra C, Mori A, Aiso S, Ito M. (2013) Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice. J Immunol.191(6):2890-9.
（2）Wunderlich M; Chou FS; Link KA; Mizukawa B; Perry RL; Carroll M; Mulloy JC. 2010. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24(10):1785-8.
（3）Billerbeck E; Barry WT; Mu K; Dorner M; Rice CM; Ploss A. 2011. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2R{gamma}null humanized mice. Blood 117(11):3076-86.
（4）Coughlan AM; Harmon C; Whelan S; O'Brien EC; O'Reilly VP; Crotty P; Kelly P; Ryan M; Hickey FB; O'Farrelly C; Little MA. 2016. Myeloid Engraftment in Humanized Mice: Impact of Granulocyte-Colony Stimulating Factor Treatment and Transgenic Mouse Strain. Stem Cells Dev 25(7):530-41.
